Meeting
2014 ASCO Annual Meeting
IMMU-132, an SN-38 antibody-drug conjugate (ADC) targeting Τrop-2, as a novel platform for the therapy of diverse metastatic solid cancers: Clinical results.
Authors
Alexander Starodub
Indiana University Health Goshen Center for Cancer Care, Goshen, IN
Alexander Starodub , Allyson J. Ocean , Michael J. Guarino , Vincent J. Picozzi , Sajeve Samuel Thomas , Wells A. Messersmith , Manish A. Shah , Linda T. Vahdat , Ellen Chuang , Bruce S. Lin , Serengulam V. Govindan , Pius P Maliakal , William A. Wegener , Steven A. Hamburger , Robert M. Sharkey , David M. Goldenberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Other
Clinical Trial Registration Number
NCT01631552
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 3032)
DOI
10.1200/jco.2014.32.15_suppl.3032
Abstract #
3032
Poster Bd #
24
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): Results from a phase II study.
First Author: Rachel Occhiogrosso Abelman
Poster
2020 ASCO Virtual Scientific Program
TROPiCS–03: A phase II open-label study of sacituzumab govitecan (SG) in patients with metastatic solid tumors.
First Author: Ashish Saxena
Poster
2015 Gastrointestinal Cancers Symposium
Phase I/II trial of IMMU-132 (isactuzumab govitecan), an anti-Trop-2-SN-38 antibody drug conjugate (ADC): Results in patients with metastatic gastrointestinal (GI) cancers.
First Author: Alexander Starodub
Poster
2014 ASCO Annual Meeting
Characterization of an anti-Τrop-2-SN-38 antibody-drug conjugate (IMMU-132) with potent activity against solid cancers.
First Author: David M. Goldenberg